Sequential Immunosuppressive Therapy in Progressive IgA Nephropathy
Backgrounds: Cyclophosphamide and high-dose steroids have been used as limited induction therapy in progressive IgA nephropathy (IgAN) to reduce the loss of renal function and proteinuria. We evaluated the effect of cyclophosphamide pulses (CyP) and mycophenolic acid (MPA) as sequential therapy on r...
Gespeichert in:
Veröffentlicht in: | Contributions to nephrology 2007-01, Vol.157, p.109-113 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 113 |
---|---|
container_issue | |
container_start_page | 109 |
container_title | Contributions to nephrology |
container_volume | 157 |
creator | Rasche, Franz Maximilian Keller, Frieder von Müller, Lutz Czock, David Lepper, Philipp M. |
description | Backgrounds: Cyclophosphamide and high-dose steroids have been used as limited induction therapy in progressive IgA nephropathy (IgAN) to reduce the loss of renal function and proteinuria. We evaluated the effect of cyclophosphamide pulses (CyP) and mycophenolic acid (MPA) as sequential therapy on renal function in patients with progressive IgAN. Methods: Twenty patients with progressive IgAN and advanced renal failure (median GFR 22 ml/min per 1.73m2) and further disease activity (▿GFR -0.8 ml/min per month) after cyclophosphamide (CyP; n = 18) or steroid pulse therapy (n = 2) were treated with mycophenolate mofetil 1 g per day for a median of 27 months. Results: The monthly loss of renal function was significantly reduced in linear regression analysis from -2.4 ml/min before CyP to -0.12 ml/min with CyP/MPA (p = 0.0009). Estimated renal survival time was significantly prolonged by a median of 65 months (p = 0.0014). Proteinuria decreased significantly from 1.7 to 0.4 g/l during MPA treatment (p = 0.015). In Cox regression analysis, only proteinuria 1.0g/l was an independent risk factor for doubling of creatinine during CyP/MPA treatment (p = 0.03). Conclusion: A sequential therapy with CyP/MPA may arrest or slow down the loss of renal function and reduces proteinuria even in patients who passed the so called ‘point of no return’ with progressive IgAN. |
doi_str_mv | 10.1159/000102313 |
format | Article |
fullrecord | <record><control><sourceid>pubmed_karge</sourceid><recordid>TN_cdi_pubmed_primary_17495446</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>17495446</sourcerecordid><originalsourceid>FETCH-LOGICAL-k195t-6d731416c020781d56c24075bf98bad0ba19792a3a32427efd5e97750dfb99303</originalsourceid><addsrcrecordid>eNqFkEtLAzEUheMLW2sX_gEZFy5H7807y1J8FIoK1vWQaTLt2E4nJh2h_95Cde3qwOHjg3MIuUK4QxTmHgAQKEN2RC4YQw3IpaLHpI9S0pwqTU_I0CjNNAihqZbilPSBAc0Fct4jw5Q-9w6gxlCtzkkPFTeCc9kn43f_1fnNtrbrbNI03aZNXQjRp1R_-2y29NGGXVZvsrfYLv7qyWKUvfiwjG2w2-XukpxVdp388DcH5OPxYTZ-zqevT5PxaJqv0IhtLp1iyFHOgYLS6IScUw5KlJXRpXVQWjTKUMsso5wqXznhjVICXFUaw4ANyPXBG7qy8a4IsW5s3BV_a_bAzQFY2bjwsfBl265S8rH2qTg8uGdu_2OK4Cr2A2thaHE</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Sequential Immunosuppressive Therapy in Progressive IgA Nephropathy</title><source>MEDLINE</source><source>Karger Book Series</source><creator>Rasche, Franz Maximilian ; Keller, Frieder ; von Müller, Lutz ; Czock, David ; Lepper, Philipp M.</creator><contributor>Tomino Y</contributor><creatorcontrib>Rasche, Franz Maximilian ; Keller, Frieder ; von Müller, Lutz ; Czock, David ; Lepper, Philipp M. ; Tomino Y</creatorcontrib><description>Backgrounds: Cyclophosphamide and high-dose steroids have been used as limited induction therapy in progressive IgA nephropathy (IgAN) to reduce the loss of renal function and proteinuria. We evaluated the effect of cyclophosphamide pulses (CyP) and mycophenolic acid (MPA) as sequential therapy on renal function in patients with progressive IgAN. Methods: Twenty patients with progressive IgAN and advanced renal failure (median GFR 22 ml/min per 1.73m2) and further disease activity (▿GFR -0.8 ml/min per month) after cyclophosphamide (CyP; n = 18) or steroid pulse therapy (n = 2) were treated with mycophenolate mofetil 1 g per day for a median of 27 months. Results: The monthly loss of renal function was significantly reduced in linear regression analysis from -2.4 ml/min before CyP to -0.12 ml/min with CyP/MPA (p = 0.0009). Estimated renal survival time was significantly prolonged by a median of 65 months (p = 0.0014). Proteinuria decreased significantly from 1.7 to 0.4 g/l during MPA treatment (p = 0.015). In Cox regression analysis, only proteinuria 1.0g/l was an independent risk factor for doubling of creatinine during CyP/MPA treatment (p = 0.03). Conclusion: A sequential therapy with CyP/MPA may arrest or slow down the loss of renal function and reduces proteinuria even in patients who passed the so called ‘point of no return’ with progressive IgAN.</description><identifier>ISSN: 0302-5144</identifier><identifier>ISBN: 9783805582865</identifier><identifier>ISBN: 3805582862</identifier><identifier>EISSN: 1662-2782</identifier><identifier>EISBN: 3318014672</identifier><identifier>EISBN: 9783318014679</identifier><identifier>DOI: 10.1159/000102313</identifier><identifier>PMID: 17495446</identifier><language>eng</language><publisher>Basel, Switzerland: S. Karger AG</publisher><subject><![CDATA[Adult ; Aged ; Anti-Inflammatory Agents, Non-Steroidal - administration & dosage ; Chapter ; Cyclophosphamide - administration & dosage ; Disease Progression ; Female ; Glomerulonephritis, IGA - drug therapy ; Humans ; Immunosuppressive Agents - administration & dosage ; Male ; Middle Aged ; Mycophenolic Acid - administration & dosage ; Mycophenolic Acid - analogs & derivatives ; Prospective Studies ; Pulse Therapy, Drug ; Renal Insufficiency - drug therapy ; Steroids - administration & dosage]]></subject><ispartof>Contributions to nephrology, 2007-01, Vol.157, p.109-113</ispartof><rights>2007 S. Karger AG, Basel</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,775,776,780,789,26059,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17495446$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Tomino Y</contributor><creatorcontrib>Rasche, Franz Maximilian</creatorcontrib><creatorcontrib>Keller, Frieder</creatorcontrib><creatorcontrib>von Müller, Lutz</creatorcontrib><creatorcontrib>Czock, David</creatorcontrib><creatorcontrib>Lepper, Philipp M.</creatorcontrib><title>Sequential Immunosuppressive Therapy in Progressive IgA Nephropathy</title><title>Contributions to nephrology</title><addtitle>Contrib Nephrol</addtitle><description>Backgrounds: Cyclophosphamide and high-dose steroids have been used as limited induction therapy in progressive IgA nephropathy (IgAN) to reduce the loss of renal function and proteinuria. We evaluated the effect of cyclophosphamide pulses (CyP) and mycophenolic acid (MPA) as sequential therapy on renal function in patients with progressive IgAN. Methods: Twenty patients with progressive IgAN and advanced renal failure (median GFR 22 ml/min per 1.73m2) and further disease activity (▿GFR -0.8 ml/min per month) after cyclophosphamide (CyP; n = 18) or steroid pulse therapy (n = 2) were treated with mycophenolate mofetil 1 g per day for a median of 27 months. Results: The monthly loss of renal function was significantly reduced in linear regression analysis from -2.4 ml/min before CyP to -0.12 ml/min with CyP/MPA (p = 0.0009). Estimated renal survival time was significantly prolonged by a median of 65 months (p = 0.0014). Proteinuria decreased significantly from 1.7 to 0.4 g/l during MPA treatment (p = 0.015). In Cox regression analysis, only proteinuria 1.0g/l was an independent risk factor for doubling of creatinine during CyP/MPA treatment (p = 0.03). Conclusion: A sequential therapy with CyP/MPA may arrest or slow down the loss of renal function and reduces proteinuria even in patients who passed the so called ‘point of no return’ with progressive IgAN.</description><subject>Adult</subject><subject>Aged</subject><subject>Anti-Inflammatory Agents, Non-Steroidal - administration & dosage</subject><subject>Chapter</subject><subject>Cyclophosphamide - administration & dosage</subject><subject>Disease Progression</subject><subject>Female</subject><subject>Glomerulonephritis, IGA - drug therapy</subject><subject>Humans</subject><subject>Immunosuppressive Agents - administration & dosage</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Mycophenolic Acid - administration & dosage</subject><subject>Mycophenolic Acid - analogs & derivatives</subject><subject>Prospective Studies</subject><subject>Pulse Therapy, Drug</subject><subject>Renal Insufficiency - drug therapy</subject><subject>Steroids - administration & dosage</subject><issn>0302-5144</issn><issn>1662-2782</issn><isbn>9783805582865</isbn><isbn>3805582862</isbn><isbn>3318014672</isbn><isbn>9783318014679</isbn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkEtLAzEUheMLW2sX_gEZFy5H7807y1J8FIoK1vWQaTLt2E4nJh2h_95Cde3qwOHjg3MIuUK4QxTmHgAQKEN2RC4YQw3IpaLHpI9S0pwqTU_I0CjNNAihqZbilPSBAc0Fct4jw5Q-9w6gxlCtzkkPFTeCc9kn43f_1fnNtrbrbNI03aZNXQjRp1R_-2y29NGGXVZvsrfYLv7qyWKUvfiwjG2w2-XukpxVdp388DcH5OPxYTZ-zqevT5PxaJqv0IhtLp1iyFHOgYLS6IScUw5KlJXRpXVQWjTKUMsso5wqXznhjVICXFUaw4ANyPXBG7qy8a4IsW5s3BV_a_bAzQFY2bjwsfBl265S8rH2qTg8uGdu_2OK4Cr2A2thaHE</recordid><startdate>20070101</startdate><enddate>20070101</enddate><creator>Rasche, Franz Maximilian</creator><creator>Keller, Frieder</creator><creator>von Müller, Lutz</creator><creator>Czock, David</creator><creator>Lepper, Philipp M.</creator><general>S. Karger AG</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>20070101</creationdate><title>Sequential Immunosuppressive Therapy in Progressive IgA Nephropathy</title><author>Rasche, Franz Maximilian ; Keller, Frieder ; von Müller, Lutz ; Czock, David ; Lepper, Philipp M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-k195t-6d731416c020781d56c24075bf98bad0ba19792a3a32427efd5e97750dfb99303</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Anti-Inflammatory Agents, Non-Steroidal - administration & dosage</topic><topic>Chapter</topic><topic>Cyclophosphamide - administration & dosage</topic><topic>Disease Progression</topic><topic>Female</topic><topic>Glomerulonephritis, IGA - drug therapy</topic><topic>Humans</topic><topic>Immunosuppressive Agents - administration & dosage</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Mycophenolic Acid - administration & dosage</topic><topic>Mycophenolic Acid - analogs & derivatives</topic><topic>Prospective Studies</topic><topic>Pulse Therapy, Drug</topic><topic>Renal Insufficiency - drug therapy</topic><topic>Steroids - administration & dosage</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rasche, Franz Maximilian</creatorcontrib><creatorcontrib>Keller, Frieder</creatorcontrib><creatorcontrib>von Müller, Lutz</creatorcontrib><creatorcontrib>Czock, David</creatorcontrib><creatorcontrib>Lepper, Philipp M.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Contributions to nephrology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rasche, Franz Maximilian</au><au>Keller, Frieder</au><au>von Müller, Lutz</au><au>Czock, David</au><au>Lepper, Philipp M.</au><au>Tomino Y</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Sequential Immunosuppressive Therapy in Progressive IgA Nephropathy</atitle><jtitle>Contributions to nephrology</jtitle><addtitle>Contrib Nephrol</addtitle><date>2007-01-01</date><risdate>2007</risdate><volume>157</volume><spage>109</spage><epage>113</epage><pages>109-113</pages><issn>0302-5144</issn><eissn>1662-2782</eissn><isbn>9783805582865</isbn><isbn>3805582862</isbn><eisbn>3318014672</eisbn><eisbn>9783318014679</eisbn><abstract>Backgrounds: Cyclophosphamide and high-dose steroids have been used as limited induction therapy in progressive IgA nephropathy (IgAN) to reduce the loss of renal function and proteinuria. We evaluated the effect of cyclophosphamide pulses (CyP) and mycophenolic acid (MPA) as sequential therapy on renal function in patients with progressive IgAN. Methods: Twenty patients with progressive IgAN and advanced renal failure (median GFR 22 ml/min per 1.73m2) and further disease activity (▿GFR -0.8 ml/min per month) after cyclophosphamide (CyP; n = 18) or steroid pulse therapy (n = 2) were treated with mycophenolate mofetil 1 g per day for a median of 27 months. Results: The monthly loss of renal function was significantly reduced in linear regression analysis from -2.4 ml/min before CyP to -0.12 ml/min with CyP/MPA (p = 0.0009). Estimated renal survival time was significantly prolonged by a median of 65 months (p = 0.0014). Proteinuria decreased significantly from 1.7 to 0.4 g/l during MPA treatment (p = 0.015). In Cox regression analysis, only proteinuria 1.0g/l was an independent risk factor for doubling of creatinine during CyP/MPA treatment (p = 0.03). Conclusion: A sequential therapy with CyP/MPA may arrest or slow down the loss of renal function and reduces proteinuria even in patients who passed the so called ‘point of no return’ with progressive IgAN.</abstract><cop>Basel, Switzerland</cop><pub>S. Karger AG</pub><pmid>17495446</pmid><doi>10.1159/000102313</doi><tpages>5</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0302-5144 |
ispartof | Contributions to nephrology, 2007-01, Vol.157, p.109-113 |
issn | 0302-5144 1662-2782 |
language | eng |
recordid | cdi_pubmed_primary_17495446 |
source | MEDLINE; Karger Book Series |
subjects | Adult Aged Anti-Inflammatory Agents, Non-Steroidal - administration & dosage Chapter Cyclophosphamide - administration & dosage Disease Progression Female Glomerulonephritis, IGA - drug therapy Humans Immunosuppressive Agents - administration & dosage Male Middle Aged Mycophenolic Acid - administration & dosage Mycophenolic Acid - analogs & derivatives Prospective Studies Pulse Therapy, Drug Renal Insufficiency - drug therapy Steroids - administration & dosage |
title | Sequential Immunosuppressive Therapy in Progressive IgA Nephropathy |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T02%3A05%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_karge&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Sequential%20Immunosuppressive%20Therapy%20in%20Progressive%20IgA%20Nephropathy&rft.jtitle=Contributions%20to%20nephrology&rft.au=Rasche,%20Franz%20Maximilian&rft.date=2007-01-01&rft.volume=157&rft.spage=109&rft.epage=113&rft.pages=109-113&rft.issn=0302-5144&rft.eissn=1662-2782&rft.isbn=9783805582865&rft.isbn_list=3805582862&rft_id=info:doi/10.1159/000102313&rft_dat=%3Cpubmed_karge%3E17495446%3C/pubmed_karge%3E%3Curl%3E%3C/url%3E&rft.eisbn=3318014672&rft.eisbn_list=9783318014679&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/17495446&rfr_iscdi=true |